₹103.49
+2.89% today
· 30d -4.62%
as of 2026-11-09
Price · Daily Candles
“Themis Medicare grapples with revenue dip, but profit spikes and strong DII interest offer a glimmer.”
Themis Medicare's Q4 2025 revenue fell 3.92% YoY to ₹90 Cr, contributing to a 31.45% annual profit decline in FY25. Despite muted growth signals from ML models, quarterly net profit surged 1843.69% YoY. A relatively low P/B of 2.6 and dividend yield of 0.5% suggest some value, though the stock trades below its 52-week high by 39.32%.
BULL CASE
+Net profit in Q4 2025 drastically improved by 1843.69% YoY to ₹10 Cr.
+The 1-month return for the stock is a positive 10.77%, with 1-week returns at 7.88%.
+FII shareholding increased by 0.06% QoQ to 0.11% in Q4 2026.
+The company's PE ratio is 33.15, lower than industry peers like Divis Lab (69.81), indicating a potentially cheaper valuation.
+RSI(14) is at 66.82, in bullish territory with moderate strength.
BEAR CASE
−Q4 2025 revenue declined by 3.92% YoY to ₹90 Cr.
−Net profit for FY25 saw a significant decrease of 31.45% YoY.
−The 1-year return is a negative 33.3%, and the stock is 39.32% off its 52-week high of ₹176.0.
−ML models predict weak sales growth (rank 0.321) and neutral EBIT/FCF growth (ranks between 0.366 and 0.433) in the near term.
⟳ What Changed
₹ Latest Earnings · Q ending 2025-12-31
REVENUE
₹90 Cr
-3.92% YoY
NET PROFIT
₹10 Cr
+1843.69% YoY
OPM
12.12%
+2.05pp YoY
EPS
₹1.1
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-12.5%, h2=+6.3%, h3=+3.3% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
Themis Medicare's PE ratio of 33.15 and ROCE of 10.0% position it below sector leaders like Sun Pharma (PE 40.41, ROCE 22.46%) and Dr. Reddy's (PE 19.55, ROCE 27.63%), suggesting a more modest valuation and efficiency profile.
PEERPEROCE %
THEMISMED32.1110.0
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒
42
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
UNDERPERFORMER
20
Valuation
FAIR
40
Growth
MUTED
34
Profitability
DECENT
58
Technicals
WEAK
47
Risk
MODERATE
50
Key Stats
P/B
2.6
52W HIGH
₹140.6
OFF HIGH
-26.39%
DIV YIELD
0.5%
MKT CAP
₹958 Cr
◉ Active Signals
MACDNeutral1.3664
RSI(14)Neutral50.25
⧉ Strategy Fit 🔒